✓ Every entry linked to its official government source

Clinical-trial readouts & FDA AdComm meetings — every entry source-anchored.

Upcoming clinical-trial readout windows (from ClinicalTrials.gov) and FDA Advisory Committee (AdComm) meetings (from the Federal Register), each linked to its official record and clearly labelled confirmed (a scheduled FDA meeting or completed event) or estimated (the sponsor's projected trial-completion date). Public scheduling data, not investment advice.

See the calendar → Get the feed / API

What "source-anchored" means here

Every row is read directly from an official government field and links straight back to it, stamped with the date we last checked. We do not dress up an estimate as a fixed date: trial-readout rows carry the sponsor's estimated primary-completion date (which can slip), while FDA AdComm meetings carry a confirmed, scheduled date from the Federal Register Notice of Meeting. Each row says which it is, and you can audit it in one click.

601

upcoming source-anchored catalysts

600

trial primary-completion / readout dates EST

75

FDA AdComm meetings CONFIRMED

266

mapped to a public ticker

Most upcoming entries are clinical-trial readout windows carrying the sponsor's estimated primary-completion date (it can slip). FDA AdComm meetings carry a confirmed scheduled date. Every row is labelled and linked to its official source.

Soonest upcoming catalysts

Source-checked 2026-08-06 · refreshed daily · full calendar →

Date	Event	Company	Drug	Official source & verification
2026-08-06 today ESTIMATED	READOUT A Study of Apremilast in Pediatric Participants in Children With Mild to Moderat Phase 3 · Plaque Psoriasis	AMGN AMGEN INC	Apremilast	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-06 today ESTIMATED	READOUT A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to S Phase 2 · Non-alcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis	Merck Sharp & Dohme LLC	Efinopegdutide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-07 in 1d ESTIMATED	READOUT A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizum Phase 3 · Axial Spondyloarthritis, Ankylosing Spondylitis	UCB Biopharma SRL	Bimekizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-08 in 2d ESTIMATED	READOUT A Phase III Control Study of the Safety and Immunogenicity of vYF in Pediatric P Phase 3 · Yellow Fever Immunization	SNY Sanofi	Yellow fever vaccine (live), Yellow feve	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-10 in 4d ESTIMATED	READOUT A Study of Rozanolixizumab in Pediatric Study Participants With Moderate to Seve Phase 2/3 · Generalized Myasthenia Gravis	UCB Biopharma SRL	rozanolixizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-10 in 4d ESTIMATED	READOUT A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Pa Phase 3 · NonSegmental Vitiligo	INCY INCYTE CORP	Ruxolitinib Cream, Vehicle Cream	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-12 in 6d ESTIMATED	READOUT ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects Wi Phase 2 · Ovarian Cancer	USWM CT, LLC	Autologous genetically modified ADP-A2M4	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-12 in 6d ESTIMATED	READOUT A Clinical Study of Enlicitide in Participants With High Cholesterol (MK-0616-03 Phase 3 · Hyperlipidemia	Merck Sharp & Dohme LLC	Enlicitide, Rosuvastatin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-13 in 7d ESTIMATED	READOUT A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Phase 2 · Urticaria Chronic	JSPR Jasper Therapeutics, Inc.	Briquilimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-13 in 7d ESTIMATED	READOUT Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity a Phase 2 · Overweight, Type 2 Diabetes	Zealand Pharma	Petrelintide	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-13 in 7d ESTIMATED	READOUT Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidia Phase 3 · Vulvovaginal Candidiases, Vulvovaginal Candidiasis, Genital	pH-D Feminine Health LLC	Boric acid	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-14 in 8d ESTIMATED	READOUT Endoscopic Evidence of Maintenance of Healing With Oral NEXIUM in Patients 1 to Phase 3 · Erosive Esophagitis	AZN ASTRAZENECA PLC	Nexium 20mg, Nexium 10mg	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-14 in 8d ESTIMATED	READOUT Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers. Phase 4 · Diabetic Foot Ulcer (DFU), Amnio-Maxx	Royal Biologics	Amnio-Maxx® Dual Layer Amnion Patch	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-15 in 9d ESTIMATED	READOUT Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years Wi Phase 2/3 · Hemophilia	Genzyme, a Sanofi Company	Fitusiran	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-15 in 9d ESTIMATED	READOUT The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP5 Phase 1/2 · Advanced Solid Tumor, Advanced Malignant Neoplasm	PMVP PMV Pharmaceuticals, Inc.	rezatapopt, pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-17 in 11d ESTIMATED	READOUT Safety, Tolerability, and Pharmacokinetics of Exidavnemab in Patients With Parki Phase 2 · Parkinson Disease, Multiple System Atrophy	BioArctic AB	exidavnemab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-17 in 11d ESTIMATED	READOUT A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Stud Phase 2 · Chronic Obstructive Pulmonary Disease	Verona Pharma, Inc., a subsidiary	Ensifentrine 3 mg, Glycopyrrolate 21.25	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-18 in 12d ESTIMATED	READOUT A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancer Phase 2 · Gastrointestinal Cancer	Merck Sharp & Dohme LLC	Raludotatug Deruxtecan (R-DXd)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-19 in 13d ESTIMATED	READOUT A Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Phase 3 · Sjogren's Syndrome	AMGN AMGEN INC	Dazodalibep	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-19 in 13d ESTIMATED	READOUT A Study to Evaluate the Effectiveness of Long-acting (LA) Cabotegravir (CAB) + R Phase 3 · HIV Infections	ViiV Healthcare	CAB LA + RPV LA, Oral ART	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-20 in 14d ESTIMATED	READOUT A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps Peop Phase 2 · Chronic Kidney Disease	Boehringer Ingelheim	Vicadrostat, Empagliflozin	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-21 in 15d ESTIMATED	READOUT Avelumab Program Rollover Study Phase 3 · Solid Tumors	EMD Serono Research & Development	Avelumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-21 in 15d ESTIMATED	READOUT Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participan Phase 1/2 · Carcinoma, Renal Cell	Merck Sharp & Dohme LLC	Pembrolizumab, Favezelimab/Pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-21 in 15d ESTIMATED	READOUT Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participan Phase 1/2 · Carcinoma, Renal Cell	Merck Sharp & Dohme LLC	Pembrolizumab, MK-4830, Belzutifan, Lenv	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change
2026-08-21 in 15d ESTIMATED	READOUT A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults Phase 3 · Dravet Syndrome	Longboard Pharmaceuticals	LP352	ClinicalTrials.gov ↗ ✓ Source-checked 2026-08-06 Sponsor-projected date — can change